 | • レポートコード：D0GIR-00150 • 出版社/出版日：GlobalInfoResearch / 2020年9月18日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、106ページ • 納品方法：Eメール • 産業分類：医療、製薬、バイオ |
| Single User | ￥515,040 (USD3,480) | ▷ お問い合わせ |
| Multi User | ￥772,560 (USD5,220) | ▷ お問い合わせ |
| Corporate User | ￥1,030,080 (USD6,960) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本調査レポートでは、抗体薬物複合体（ADC）の世界市場を広く調査・分析し、今後の市場展望をまとめております。抗体薬物複合体（ADC）の種類別市場規模（シアトルジェネティクステクノロジー、イムノジェンテクノロジー、イムノメディックステクノロジー）、用途別市場規模（病院、クリニック、その他）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど）、市場動向、企業別販売量と市場シェアなどの情報を掲載しています。 ・市場概要 ・企業情報（販売量、市場シェア、製品概要、SWOT分析）：Roche、AbbVie、Genmab、Pfizer、Takeda Pharmaceuticals、Novartis、ADC Therapeutics、Seattle Genetics、Bayer、AbGenomics、Astellas Pharma、Kairos Therapeutics ・地域別グローバル市場分析 2015年-2020年 ・抗体薬物複合体（ADC）の北米市場（アメリカ、カナダ、メキシコ） ・抗体薬物複合体（ADC）のヨーロッパ市場（ドイツ、イギリス、フランス、ロシア、イタリア） ・抗体薬物複合体（ADC）のアジア市場（中国、日本、韓国、インド、東南アジア、オーストラリア） ・抗体薬物複合体（ADC）の南米市場（ブラジル、アルゼンチン） ・抗体薬物複合体（ADC）の中東・アフリカ市場（サウジアラビア、トルコ、エジプト、南アフリカ） ・種類別分析：シアトルジェネティクステクノロジー、イムノジェンテクノロジー、イムノメディックステクノロジー ・用途別分析：病院、クリニック、その他 ・地域別市場規模予測 2021年-2025年 ・調査の結果・結論 |
Market Overview
The global Antibody Drug Conjugates (ADCs) market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019.
The Antibody Drug Conjugates (ADCs) market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
Market segmentation
Antibody Drug Conjugates (ADCs) market is split by Type and by Application. For the period 2015-2025, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
By Type, Antibody Drug Conjugates (ADCs) market has been segmented into:
Seattle Genetics Technology
ImmunoGen Technology
Immunomedics Technology
By Application, Antibody Drug Conjugates (ADCs) has been segmented into:
Hospital
Clinics
Others
Regions and Countries Level Analysis
Regional analysis is another highly comprehensive part of the research and analysis study of the global Antibody Drug Conjugates (ADCs) market presented in the report. This section sheds light on the sales growth of different regional and country-level Antibody Drug Conjugates (ADCs) markets. For the historical and forecast period 2015 to 2025, it provides detailed and accurate country-wise volume analysis and region-wise market size analysis of the global Antibody Drug Conjugates (ADCs) market.
The report offers in-depth assessment of the growth and other aspects of the Antibody Drug Conjugates (ADCs) market in important countries (regions), including:
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Australia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Competitive Landscape and Antibody Drug Conjugates (ADCs) Market Share Analysis
Antibody Drug Conjugates (ADCs) competitive landscape provides details by vendors, including company overview, company total revenue (financials), market potential, global presence, Antibody Drug Conjugates (ADCs) sales and revenue generated, market share, price, production sites and facilities, SWOT analysis, product launch. For the period 2015-2020, this study provides the Antibody Drug Conjugates (ADCs) sales, revenue and market share for each player covered in this report.
The major players covered in Antibody Drug Conjugates (ADCs) are:
Roche
AbbVie
Genmab
Pfizer
Takeda Pharmaceuticals
Novartis
ADC Therapeutics
Seattle Genetics
Bayer
AbGenomics
Astellas Pharma
Kairos Therapeutics
Table of Contents
1 Antibody Drug Conjugates (ADCs) Market Overview
1.1 Product Overview and Scope of Antibody Drug Conjugates (ADCs)
1.2 Classification of Antibody Drug Conjugates (ADCs) by Type
1.2.1 Global Antibody Drug Conjugates (ADCs) Revenue by Type: 2015 VS 2019 VS 2025
1.2.2 Global Antibody Drug Conjugates (ADCs) Revenue Market Share by Type in 2019
1.2.3 Seattle Genetics Technology
1.2.4 ImmunoGen Technology
1.2.5 Immunomedics Technology
1.3 Global Antibody Drug Conjugates (ADCs) Market by Application
1.3.1 Overview: Global Antibody Drug Conjugates (ADCs) Revenue by Application: 2015 VS 2019 VS 2025
1.3.2 Hospital
1.3.3 Clinics
1.3.4 Others
1.4 Global Antibody Drug Conjugates (ADCs) Market by Regions
1.4.1 Global Antibody Drug Conjugates (ADCs) Market Size by Regions: 2015 VS 2019 VS 2025
1.4.2 Global Market Size of Antibody Drug Conjugates (ADCs) (2015-2025)
1.4.3 North America (USA, Canada and Mexico) Antibody Drug Conjugates (ADCs) Status and Prospect (2015-2025)
1.4.4 Europe (Germany, France, UK, Russia and Italy) Antibody Drug Conjugates (ADCs) Status and Prospect (2015-2025)
1.4.5 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Antibody Drug Conjugates (ADCs) Status and Prospect (2015-2025)
1.4.6 South America (Brazil, Argentina, Colombia) Antibody Drug Conjugates (ADCs) Status and Prospect (2015-2025)
1.4.7 Middle East & Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Antibody Drug Conjugates (ADCs) Status and Prospect (2015-2025)
2 Company Profiles
2.1 Roche
2.1.1 Roche Details
2.1.2 Roche Major Business and Total Revenue (Financial Highlights) Analysis
2.1.3 Roche SWOT Analysis
2.1.4 Roche Product and Services
2.1.5 Roche Antibody Drug Conjugates (ADCs) Revenue, Gross Margin and Market Share (2018-2019)
2.2 AbbVie
2.2.1 AbbVie Details
2.2.2 AbbVie Major Business and Total Revenue (Financial Highlights) Analysis
2.2.3 AbbVie SWOT Analysis
2.2.4 AbbVie Product and Services
2.2.5 AbbVie Antibody Drug Conjugates (ADCs) Revenue, Gross Margin and Market Share (2018-2019)
2.3 Genmab
2.3.1 Genmab Details
2.3.2 Genmab Major Business and Total Revenue (Financial Highlights) Analysis
2.3.3 Genmab SWOT Analysis
2.3.4 Genmab Product and Services
2.3.5 Genmab Antibody Drug Conjugates (ADCs) Revenue, Gross Margin and Market Share (2018-2019)
2.4 Pfizer
2.4.1 Pfizer Details
2.4.2 Pfizer Major Business and Total Revenue (Financial Highlights) Analysis
2.4.3 Pfizer SWOT Analysis
2.4.4 Pfizer Product and Services
2.4.5 Pfizer Antibody Drug Conjugates (ADCs) Revenue, Gross Margin and Market Share (2018-2019)
2.5 Takeda Pharmaceuticals
2.5.1 Takeda Pharmaceuticals Details
2.5.2 Takeda Pharmaceuticals Major Business and Total Revenue (Financial Highlights) Analysis
2.5.3 Takeda Pharmaceuticals SWOT Analysis
2.5.4 Takeda Pharmaceuticals Product and Services
2.5.5 Takeda Pharmaceuticals Antibody Drug Conjugates (ADCs) Revenue, Gross Margin and Market Share (2018-2019)
2.6 Novartis
2.6.1 Novartis Details
2.6.2 Novartis Major Business and Total Revenue (Financial Highlights) Analysis
2.6.3 Novartis SWOT Analysis
2.6.4 Novartis Product and Services
2.6.5 Novartis Antibody Drug Conjugates (ADCs) Revenue, Gross Margin and Market Share (2018-2019)
2.7 ADC Therapeutics
2.7.1 ADC Therapeutics Details
2.7.2 ADC Therapeutics Major Business and Total Revenue (Financial Highlights) Analysis
2.7.3 ADC Therapeutics SWOT Analysis
2.7.4 ADC Therapeutics Product and Services
2.7.5 ADC Therapeutics Antibody Drug Conjugates (ADCs) Revenue, Gross Margin and Market Share (2018-2019)
2.8 Seattle Genetics
2.8.1 Seattle Genetics Details
2.8.2 Seattle Genetics Major Business and Total Revenue (Financial Highlights) Analysis
2.8.3 Seattle Genetics SWOT Analysis
2.8.4 Seattle Genetics Product and Services
2.8.5 Seattle Genetics Antibody Drug Conjugates (ADCs) Revenue, Gross Margin and Market Share (2018-2019)
2.9 Bayer
2.9.1 Bayer Details
2.9.2 Bayer Major Business and Total Revenue (Financial Highlights) Analysis
2.9.3 Bayer SWOT Analysis
2.9.4 Bayer Product and Services
2.9.5 Bayer Antibody Drug Conjugates (ADCs) Revenue, Gross Margin and Market Share (2018-2019)
2.10 AbGenomics
2.10.1 AbGenomics Details
2.10.2 AbGenomics Major Business and Total Revenue (Financial Highlights) Analysis
2.10.3 AbGenomics SWOT Analysis
2.10.4 AbGenomics Product and Services
2.10.5 AbGenomics Antibody Drug Conjugates (ADCs) Revenue, Gross Margin and Market Share (2018-2019)
2.11 Astellas Pharma
2.11.1 Astellas Pharma Details
2.11.2 Astellas Pharma Major Business and Total Revenue (Financial Highlights) Analysis
2.11.3 Astellas Pharma SWOT Analysis
2.11.4 Astellas Pharma Product and Services
2.11.5 Astellas Pharma Antibody Drug Conjugates (ADCs) Revenue, Gross Margin and Market Share (2018-2019)
2.12 Kairos Therapeutics
2.12.1 Kairos Therapeutics Details
2.12.2 Kairos Therapeutics Major Business and Total Revenue (Financial Highlights) Analysis
2.12.3 Kairos Therapeutics SWOT Analysis
2.12.4 Kairos Therapeutics Product and Services
2.12.5 Kairos Therapeutics Antibody Drug Conjugates (ADCs) Revenue, Gross Margin and Market Share (2018-2019)
3 Market Competition, by Players
3.1 Global Antibody Drug Conjugates (ADCs) Revenue and Share by Players (2015-2020)
3.2 Market Concentration Rate
3.2.1 Top 5 Antibody Drug Conjugates (ADCs) Players Market Share
3.2.2 Top 10 Antibody Drug Conjugates (ADCs) Players Market Share
3.3 Market Competition Trend
4 Market Size by Regions
4.1 Global Antibody Drug Conjugates (ADCs) Revenue and Market Share by Regions
4.2 North America Antibody Drug Conjugates (ADCs) Revenue and Growth Rate (2015-2020)
4.3 Europe Antibody Drug Conjugates (ADCs) Revenue and Growth Rate (2015-2020)
4.4 Asia-Pacific Antibody Drug Conjugates (ADCs) Revenue and Growth Rate (2015-2020)
4.5 South America Antibody Drug Conjugates (ADCs) Revenue and Growth Rate (2015-2020)
4.6 Middle East & Africa Antibody Drug Conjugates (ADCs) Revenue and Growth Rate (2015-2020)
5 North America Antibody Drug Conjugates (ADCs) Revenue by Countries
5.1 North America Antibody Drug Conjugates (ADCs) Revenue by Countries (2015-2020)
5.2 USA Antibody Drug Conjugates (ADCs) Revenue and Growth Rate (2015-2020)
5.3 Canada Antibody Drug Conjugates (ADCs) Revenue and Growth Rate (2015-2020)
5.4 Mexico Antibody Drug Conjugates (ADCs) Revenue and Growth Rate (2015-2020)
6 Europe Antibody Drug Conjugates (ADCs) Revenue by Countries
6.1 Europe Antibody Drug Conjugates (ADCs) Revenue by Countries (2015-2020)
6.2 Germany Antibody Drug Conjugates (ADCs) Revenue and Growth Rate (2015-2020)
6.3 UK Antibody Drug Conjugates (ADCs) Revenue and Growth Rate (2015-2020)
6.4 France Antibody Drug Conjugates (ADCs) Revenue and Growth Rate (2015-2020)
6.5 Russia Antibody Drug Conjugates (ADCs) Revenue and Growth Rate (2015-2020)
6.6 Italy Antibody Drug Conjugates (ADCs) Revenue and Growth Rate (2015-2020)
7 Asia-Pacific Antibody Drug Conjugates (ADCs) Revenue by Countries
7.1 Asia-Pacific Antibody Drug Conjugates (ADCs) Revenue by Countries (2015-2020)
7.2 China Antibody Drug Conjugates (ADCs) Revenue and Growth Rate (2015-2020)
7.3 Japan Antibody Drug Conjugates (ADCs) Revenue and Growth Rate (2015-2020)
7.4 Korea Antibody Drug Conjugates (ADCs) Revenue and Growth Rate (2015-2020)
7.5 India Antibody Drug Conjugates (ADCs) Revenue and Growth Rate (2015-2020)
7.6 Southeast Asia Antibody Drug Conjugates (ADCs) Revenue and Growth Rate (2015-2020)
8 South America Antibody Drug Conjugates (ADCs) Revenue by Countries
8.1 South America Antibody Drug Conjugates (ADCs) Revenue by Countries (2015-2020)
8.2 Brazil Antibody Drug Conjugates (ADCs) Revenue and Growth Rate (2015-2020)
8.3 Argentina Antibody Drug Conjugates (ADCs) Revenue and Growth Rate (2015-2020)
9 Middle East & Africa Revenue Antibody Drug Conjugates (ADCs) by Countries
9.1 Middle East & Africa Antibody Drug Conjugates (ADCs) Revenue by Countries (2015-2020)
9.2 Saudi Arabia Antibody Drug Conjugates (ADCs) Revenue and Growth Rate (2015-2020)
9.3 UAE Antibody Drug Conjugates (ADCs) Revenue and Growth Rate (2015-2020)
9.4 Egypt Antibody Drug Conjugates (ADCs) Revenue and Growth Rate (2015-2020)
9.5 South Africa Antibody Drug Conjugates (ADCs) Revenue and Growth Rate (2015-2020)
10 Market Size Segment by Type
10.1 Global Antibody Drug Conjugates (ADCs) Revenue and Market Share by Type (2015-2020)
10.2 Global Antibody Drug Conjugates (ADCs) Market Forecast by Type (2019-2024)
10.3 Seattle Genetics Technology Revenue Growth Rate (2015-2025)
10.4 ImmunoGen Technology Revenue Growth Rate (2015-2025)
10.5 Immunomedics Technology Revenue Growth Rate (2015-2025)
11 Global Antibody Drug Conjugates (ADCs) Market Segment by Application
11.1 Global Antibody Drug Conjugates (ADCs) Revenue Market Share by Application (2015-2020)
11.2 Antibody Drug Conjugates (ADCs) Market Forecast by Application (2019-2024)
11.3 Hospital Revenue Growth (2015-2020)
11.4 Clinics Revenue Growth (2015-2020)
11.5 Others Revenue Growth (2015-2020)
12 Global Antibody Drug Conjugates (ADCs) Market Size Forecast (2021-2025)
12.1 Global Antibody Drug Conjugates (ADCs) Market Size Forecast (2021-2025)
12.2 Global Antibody Drug Conjugates (ADCs) Market Forecast by Regions (2021-2025)
12.3 North America Antibody Drug Conjugates (ADCs) Revenue Market Forecast (2021-2025)
12.4 Europe Antibody Drug Conjugates (ADCs) Revenue Market Forecast (2021-2025)
12.5 Asia-Pacific Antibody Drug Conjugates (ADCs) Revenue Market Forecast (2021-2025)
12.6 South America Antibody Drug Conjugates (ADCs) Revenue Market Forecast (2021-2025)
12.7 Middle East & Africa Antibody Drug Conjugates (ADCs) Revenue Market Forecast (2021-2025)
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Data Source
14.3 Disclaimer
14.4 About US
Table 1. Global Antibody Drug Conjugates (ADCs) Revenue (USD Million) by Type: 2015 VS 2019 VS 2025
Table 2. Breakdown of Antibody Drug Conjugates (ADCs) by Company Type (Tier 1, Tier 2 and Tier 3)
Table 3. Global Antibody Drug Conjugates (ADCs) Revenue (USD Million) by Application: 2015 VS 2019 VS 2025
Table 4. Global Market Antibody Drug Conjugates (ADCs) Revenue (Million USD) Comparison by Regions 2015-2025
Table 5. Roche Corporate Information, Location and Competitors
Table 6. Roche Antibody Drug Conjugates (ADCs) Major Business
Table 7. Roche Antibody Drug Conjugates (ADCs) Total Revenue (USD Million) (2017-2018)
Table 8. Roche SWOT Analysis
Table 9. Roche Antibody Drug Conjugates (ADCs) Product and Solutions
Table 10. Roche Antibody Drug Conjugates (ADCs) Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 11. AbbVie Corporate Information, Location and Competitors
Table 12. AbbVie Antibody Drug Conjugates (ADCs) Major Business
Table 13. AbbVie Antibody Drug Conjugates (ADCs) Total Revenue (USD Million) (2018-2019)
Table 14. AbbVie SWOT Analysis
Table 15. AbbVie Antibody Drug Conjugates (ADCs) Product and Solutions
Table 16. AbbVie Antibody Drug Conjugates (ADCs) Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 17. Genmab Corporate Information, Location and Competitors
Table 18. Genmab Antibody Drug Conjugates (ADCs) Major Business
Table 19. Genmab Antibody Drug Conjugates (ADCs) Total Revenue (USD Million) (2017-2018)
Table 20. Genmab SWOT Analysis
Table 21. Genmab Antibody Drug Conjugates (ADCs) Product and Solutions
Table 22. Genmab Antibody Drug Conjugates (ADCs) Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 23. Pfizer Corporate Information, Location and Competitors
Table 24. Pfizer Antibody Drug Conjugates (ADCs) Major Business
Table 25. Pfizer Antibody Drug Conjugates (ADCs) Total Revenue (USD Million) (2017-2018)
Table 26. Pfizer SWOT Analysis
Table 27. Pfizer Antibody Drug Conjugates (ADCs) Product and Solutions
Table 28. Pfizer Antibody Drug Conjugates (ADCs) Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 29. Takeda Pharmaceuticals Corporate Information, Location and Competitors
Table 30. Takeda Pharmaceuticals Antibody Drug Conjugates (ADCs) Major Business
Table 31. Takeda Pharmaceuticals Antibody Drug Conjugates (ADCs) Total Revenue (USD Million) (2017-2018)
Table 32. Takeda Pharmaceuticals SWOT Analysis
Table 33. Takeda Pharmaceuticals Antibody Drug Conjugates (ADCs) Product and Solutions
Table 34. Takeda Pharmaceuticals Antibody Drug Conjugates (ADCs) Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 35. Novartis Corporate Information, Location and Competitors
Table 36. Novartis Antibody Drug Conjugates (ADCs) Major Business
Table 37. Novartis Antibody Drug Conjugates (ADCs) Total Revenue (USD Million) (2017-2018)
Table 38. Novartis SWOT Analysis
Table 39. Novartis Antibody Drug Conjugates (ADCs) Product and Solutions
Table 40. Novartis Antibody Drug Conjugates (ADCs) Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 41. ADC Therapeutics Corporate Information, Location and Competitors
Table 42. ADC Therapeutics Antibody Drug Conjugates (ADCs) Major Business
Table 43. ADC Therapeutics Antibody Drug Conjugates (ADCs) Total Revenue (USD Million) (2017-2018)
Table 44. ADC Therapeutics SWOT Analysis
Table 45. ADC Therapeutics Antibody Drug Conjugates (ADCs) Product and Solutions
Table 46. ADC Therapeutics Antibody Drug Conjugates (ADCs) Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 47. Seattle Genetics Corporate Information, Location and Competitors
Table 48. Seattle Genetics Antibody Drug Conjugates (ADCs) Major Business
Table 49. Seattle Genetics Antibody Drug Conjugates (ADCs) Total Revenue (USD Million) (2017-2018)
Table 50. Seattle Genetics SWOT Analysis
Table 51. Seattle Genetics Antibody Drug Conjugates (ADCs) Product and Solutions
Table 52. Seattle Genetics Antibody Drug Conjugates (ADCs) Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 53. Bayer Corporate Information, Location and Competitors
Table 54. Bayer Antibody Drug Conjugates (ADCs) Major Business
Table 55. Bayer Antibody Drug Conjugates (ADCs) Total Revenue (USD Million) (2017-2018)
Table 56. Bayer SWOT Analysis
Table 57. Bayer Antibody Drug Conjugates (ADCs) Product and Solutions
Table 58. Bayer Antibody Drug Conjugates (ADCs) Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 59. AbGenomics Corporate Information, Location and Competitors
Table 60. AbGenomics Antibody Drug Conjugates (ADCs) Major Business
Table 61. AbGenomics Antibody Drug Conjugates (ADCs) Total Revenue (USD Million) (2017-2018)
Table 62. AbGenomics SWOT Analysis
Table 63. AbGenomics Antibody Drug Conjugates (ADCs) Product and Solutions
Table 64. AbGenomics Antibody Drug Conjugates (ADCs) Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 65. Astellas Pharma Corporate Information, Location and Competitors
Table 66. Astellas Pharma Antibody Drug Conjugates (ADCs) Major Business
Table 67. Astellas Pharma Antibody Drug Conjugates (ADCs) Total Revenue (USD Million) (2017-2018)
Table 68. Astellas Pharma SWOT Analysis
Table 69. Astellas Pharma Antibody Drug Conjugates (ADCs) Product and Solutions
Table 70. Astellas Pharma Antibody Drug Conjugates (ADCs) Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 71. Kairos Therapeutics Corporate Information, Location and Competitors
Table 72. Kairos Therapeutics Antibody Drug Conjugates (ADCs) Major Business
Table 73. Kairos Therapeutics Antibody Drug Conjugates (ADCs) Total Revenue (USD Million) (2017-2018)
Table 74. Kairos Therapeutics SWOT Analysis
Table 75. Kairos Therapeutics Antibody Drug Conjugates (ADCs) Product and Solutions
Table 76. Kairos Therapeutics Antibody Drug Conjugates (ADCs) Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 77. Global Antibody Drug Conjugates (ADCs) Revenue (Million USD) by Players (2015-2020)
Table 78. Global Antibody Drug Conjugates (ADCs) Revenue Share by Players (2015-2020)
Table 79. Global Antibody Drug Conjugates (ADCs) Revenue (Million USD) by Regions (2015-2020)
Table 80. Global Antibody Drug Conjugates (ADCs) Revenue Market Share by Regions (2015-2020)
Table 81. North America Antibody Drug Conjugates (ADCs) Revenue by Countries (2015-2020)
Table 82. North America Antibody Drug Conjugates (ADCs) Revenue Market Share by Countries (2015-2020)
Table 83. Europe Antibody Drug Conjugates (ADCs) Revenue (Million USD) by Countries (2015-2020)
Table 84. Asia-Pacific Antibody Drug Conjugates (ADCs) Revenue (Million USD) by Countries (2015-2020)
Table 85. South America Antibody Drug Conjugates (ADCs) Revenue by Countries (2015-2020)
Table 86. South America Antibody Drug Conjugates (ADCs) Revenue Market Share by Countries (2015-2020)
Table 87. Middle East and Africa Antibody Drug Conjugates (ADCs) Revenue (Million USD) by Countries (2015-2020)
Table 88. Middle East and Africa Antibody Drug Conjugates (ADCs) Revenue Market Share by Countries (2015-2020)
Table 89. Global Antibody Drug Conjugates (ADCs) Revenue (Million USD) by Type (2015-2020)
Table 90. Global Antibody Drug Conjugates (ADCs) Revenue Share by Type (2015-2020)
Table 91. Global Antibody Drug Conjugates (ADCs) Revenue Forecast by Type (2021-2025)
Table 92. Global Antibody Drug Conjugates (ADCs) Revenue by Application (2015-2020)
Table 93. Global Antibody Drug Conjugates (ADCs) Revenue Share by Application (2015-2020)
Table 94. Global Antibody Drug Conjugates (ADCs) Revenue Forecast by Application (2021-2025)
Table 95. Global Antibody Drug Conjugates (ADCs) Revenue (Million USD) Forecast by Regions (2021-2025)
List of Figures
Figure 1. Antibody Drug Conjugates (ADCs) Picture
Figure 2. Global Antibody Drug Conjugates (ADCs) Revenue Market Share by Type in 2019
Figure 3. Seattle Genetics Technology Picture
Figure 4. ImmunoGen Technology Picture
Figure 5. Immunomedics Technology Picture
Figure 6. Antibody Drug Conjugates (ADCs) Revenue Market Share by Application in 2019
Figure 7. Hospital Picture
Figure 8. Clinics Picture
Figure 9. Others Picture
Figure 10. Global Antibody Drug Conjugates (ADCs) Revenue (USD Million) and Growth Rate (2015-2025)
Figure 11. North America Antibody Drug Conjugates (ADCs) Revenue (Million USD) and Growth Rate (2015-2025)
Figure 12. Europe Antibody Drug Conjugates (ADCs) Revenue (Million USD) and Growth Rate (2015-2025)
Figure 13. Asia-Pacific Antibody Drug Conjugates (ADCs) Revenue (Million USD) and Growth Rate (2015-2025)
Figure 14. South America Antibody Drug Conjugates (ADCs) Revenue (Million USD) and Growth Rate (2015-2025)
Figure 15. Middle East and Africa Antibody Drug Conjugates (ADCs) Revenue (Million USD) and Growth Rate (2015-2025)
Figure 16. Global Antibody Drug Conjugates (ADCs) Revenue (Million USD) and Growth Rate (2015-2025)
Figure 17. Global Antibody Drug Conjugates (ADCs) Revenue Share by Players in 2019
Figure 18. Global Top 5 Players Antibody Drug Conjugates (ADCs) Revenue Market Share in 2019
Figure 19. Global Top 10 Players Antibody Drug Conjugates (ADCs) Revenue Market Share in 2019
Figure 20. Key Players Market Share Trend
Figure 21. Global Antibody Drug Conjugates (ADCs) Revenue (Million USD) and Growth Rate (%) (2015-2020)
Figure 22. Global Antibody Drug Conjugates (ADCs) Revenue Market Share by Regions (2015-2020)
Figure 23. Global Antibody Drug Conjugates (ADCs) Revenue Market Share by Regions in 2018
Figure 24. North America Antibody Drug Conjugates (ADCs) Revenue and Growth Rate (2015-2020)
Figure 25. Europe Antibody Drug Conjugates (ADCs) Revenue and Growth Rate (2015-2020)
Figure 26. Asia-Pacific Antibody Drug Conjugates (ADCs) Revenue and Growth Rate (2015-2020)
Figure 27. South America Antibody Drug Conjugates (ADCs) Revenue and Growth Rate (2015-2020)
Figure 28. Middle East and Africa Antibody Drug Conjugates (ADCs) Revenue and Growth Rate (2015-2020)
Figure 29. North America Antibody Drug Conjugates (ADCs) Revenue Market Share by Countries (2015-2020)
Figure 30. North America Antibody Drug Conjugates (ADCs) Revenue Market Share by Countries in 2019
Figure 31. USA Antibody Drug Conjugates (ADCs) Revenue and Growth Rate (2015-2020)
Figure 32. Canada Antibody Drug Conjugates (ADCs) Revenue and Growth Rate (2015-2020)
Figure 33. Mexico Antibody Drug Conjugates (ADCs) Revenue and Growth Rate (2015-2020)
Figure 34. Europe Antibody Drug Conjugates (ADCs) Revenue Market Share by Countries (2015-2020)
Figure 35. Europe Antibody Drug Conjugates (ADCs) Revenue Market Share by Countries in 2019
Figure 36. Germany Antibody Drug Conjugates (ADCs) Revenue and Growth Rate (2015-2020)
Figure 37. UK Antibody Drug Conjugates (ADCs) Revenue and Growth Rate (2015-2020)
Figure 38. France Antibody Drug Conjugates (ADCs) Revenue and Growth Rate (2015-2020)
Figure 39. Russia Antibody Drug Conjugates (ADCs) Revenue and Growth Rate (2015-2020)
Figure 40. Italy Antibody Drug Conjugates (ADCs) Revenue and Growth Rate (2015-2020)
Figure 41. Asia-Pacific Antibody Drug Conjugates (ADCs) Revenue Market Share by Countries (2015-2020)
Figure 42. Asia-Pacific Antibody Drug Conjugates (ADCs) Revenue Market Share by Countries in 2019
Figure 43. China Antibody Drug Conjugates (ADCs) Revenue and Growth Rate (2015-2020)
Figure 44. Japan Antibody Drug Conjugates (ADCs) Revenue and Growth Rate (2015-2020)
Figure 45. Korea Antibody Drug Conjugates (ADCs) Revenue and Growth Rate (2015-2020)
Figure 46. India Antibody Drug Conjugates (ADCs) Revenue and Growth Rate (2015-2020)
Figure 47. Southeast Asia Antibody Drug Conjugates (ADCs) Revenue and Growth Rate (2015-2020)
Figure 48. South America Antibody Drug Conjugates (ADCs) Revenue Market Share by Countries (2015-2020)
Figure 49. South America Antibody Drug Conjugates (ADCs) Revenue Market Share by Countries in 2019
Figure 50. Brazil Antibody Drug Conjugates (ADCs) Revenue and Growth Rate (2015-2020)
Figure 51. Argentina Antibody Drug Conjugates (ADCs) Revenue and Growth Rate (2015-2020)
Figure 52. Middle East and Africa Antibody Drug Conjugates (ADCs) Revenue Market Share by Countries (2015-2020)
Figure 53. Middle East and Africa Antibody Drug Conjugates (ADCs) Revenue Market Share by Countries in 2019
Figure 54. Saudi Arabia Antibody Drug Conjugates (ADCs) Revenue and Growth Rate (2015-2020)
Figure 55. UAE Antibody Drug Conjugates (ADCs) Revenue and Growth Rate (2015-2020)
Figure 56. Egypt Antibody Drug Conjugates (ADCs) Revenue and Growth Rate (2015-2020)
Figure 57. South Africa Antibody Drug Conjugates (ADCs) Revenue and Growth Rate (2015-2020)
Figure 58. Global Antibody Drug Conjugates (ADCs) Revenue Share by Type (2015-2020)
Figure 59. Global Antibody Drug Conjugates (ADCs) Revenue Share by Type in 2019
Figure 60. Global Antibody Drug Conjugates (ADCs) Market Share Forecast by Type (2021-2025)
Figure 61. Global Seattle Genetics Technology Revenue Growth Rate (2015-2020)
Figure 62. Global ImmunoGen Technology Revenue Growth Rate (2015-2020)
Figure 63. Global Immunomedics Technology Revenue Growth Rate (2015-2020)
Figure 64. Global Antibody Drug Conjugates (ADCs) Revenue Share by Application (2015-2020)
Figure 65. Global Antibody Drug Conjugates (ADCs) Revenue Share by Application in 2019
Figure 66. Global Antibody Drug Conjugates (ADCs) Market Share Forecast by Application (2021-2025)
Figure 67. Global Hospital Revenue Growth Rate (2015-2020)
Figure 68. Global Clinics Revenue Growth Rate (2015-2020)
Figure 69. Global Others Revenue Growth Rate (2015-2020)
Figure 70. Global Antibody Drug Conjugates (ADCs) Revenue (Million USD) and Growth Rate Forecast (2021-2025)
Figure 71. Global Antibody Drug Conjugates (ADCs) Revenue (Million USD) Forecast by Regions (2021-2025)
Figure 72. Global Antibody Drug Conjugates (ADCs) Revenue Market Share Forecast by Regions (2021-2025)
Figure 73. North America Antibody Drug Conjugates (ADCs) Revenue Market Forecast (2021-2025)
Figure 74. Europe Antibody Drug Conjugates (ADCs) Revenue Market Forecast (2021-2025)
Figure 75. Asia-Pacific Antibody Drug Conjugates (ADCs) Revenue Market Forecast (2021-2025)
Figure 76. South America Antibody Drug Conjugates (ADCs) Revenue Market Forecast (2021-2025)
Figure 77. Middle East and Africa Antibody Drug Conjugates (ADCs) Revenue Market Forecast (2021-2025)
Figure 78. Sales Channel: Direct Channel vs Indirect Channel
次世代抗体治療の世界市場2020年：企業別、地域別、種類・用途別 Market Overview The global Next Generation Antibody Therapeutics market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019. The Next Ge…- 抗体薬物複合体（ADC）薬物の世界市場2020年：企業別、地域別、種類・用途別 Market Overview The Antibody Drug Conjugate (ADC) Drug market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain …
- 抗体薬物コンジュゲート治療の世界市場2020年：企業別、地域別、種類・用途別 Market Overview The Antibody Drug Conjugate Therapeutics market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chai…
- フィコビリプロテインコンジュゲートの世界市場2020年：メーカー別、地域別、種類・用途別 Market Overview The global Phycobiliprotein Conjugates market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of 20.4% in the forecast period of 2020 to 2025 and will expected to reach USD 53 million by 2025, from USD 25 million in 2019. The Phycobiliprotei…
- 狂犬病モノクローナル抗体の世界市場2020年：企業別、地域別、種類・用途別 Market Overview The Rabies Monoclonal Antibody market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimiza…